Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short ...

Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers. Fiona Jones ...

Investors are gearing up for another busy week of earnings season, and some retail-investor favorites are part of the line-up ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

PNC Financial Services Group Inc. lifted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 123.8% ...